OPDP slams Kowa for Lipofen-touting email; Pharma responds to FDA's social media rules; Novo nabs EU approval for Xultophy;

> The FDA's Office of Prescription Drug Promotion jumped on Kowa Pharmaceuticals and Cipher Pharmaceuticals ($CPHMF) for "unsubstantiated claims" in an email promoting its cholesterol treatment Lipofen. Report

> Drugmakers aren't happy about the FDA's new social media rules, and they've filed their grievances with the agency as part of the rulemaking process. Report

> Novo Nordisk's ($NVO) new combination diabetes treatment Xultophy, comprising Tresiba and Victoza, won approval in Europe; the company plans to launch early next year. Release

> AstraZeneca ($AZN) posted new trial data on Bydureon, its long-acting version of exanatide, showing that it matched or beat the twice-daily version, Byetta, at helping people with diabetes control their blood sugar. Report

> Spectrum Pharmaceuticals ($SPPI) licensed two of its cancer drugs, Zevalin and Marqibo, and a Phase III candidate to CASI Pharmaceuticals ($CASI) to develop and sell in China. Report

And Finally... Merck ($MRK) and Bristol-Myers Squibb ($BMY) may be wrapping up their Sustiva patent fight with Cipla, according to newly filed court documents. Report